Cargando…

ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma

BACKGROUND: Ovarian metastatic tumors from lung adenocarcinoma are rare, and a serial study of these tumors is lacking to date. Additionally, a better understanding of the clinicopathological and molecular characteristics of metastatic tumors is needed. METHODS: Seven cases of ovarian metastasis fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Bi, Rui, Bai, Qianming, Zhu, Xiaoli, Tu, Xiaoyu, Cai, Xu, Jiang, Wenhua, Xu, Xiaoli, Tang, Shaoxian, Ge, Huijuan, Chang, Bin, Cheng, Yufan, Gan, Hualei, Zhou, Xiaoyan, Yang, Wentao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712650/
https://www.ncbi.nlm.nih.gov/pubmed/31455365
http://dx.doi.org/10.1186/s13000-019-0864-7
_version_ 1783446718745935872
author Bi, Rui
Bai, Qianming
Zhu, Xiaoli
Tu, Xiaoyu
Cai, Xu
Jiang, Wenhua
Xu, Xiaoli
Tang, Shaoxian
Ge, Huijuan
Chang, Bin
Cheng, Yufan
Gan, Hualei
Zhou, Xiaoyan
Yang, Wentao
author_facet Bi, Rui
Bai, Qianming
Zhu, Xiaoli
Tu, Xiaoyu
Cai, Xu
Jiang, Wenhua
Xu, Xiaoli
Tang, Shaoxian
Ge, Huijuan
Chang, Bin
Cheng, Yufan
Gan, Hualei
Zhou, Xiaoyan
Yang, Wentao
author_sort Bi, Rui
collection PubMed
description BACKGROUND: Ovarian metastatic tumors from lung adenocarcinoma are rare, and a serial study of these tumors is lacking to date. Additionally, a better understanding of the clinicopathological and molecular characteristics of metastatic tumors is needed. METHODS: Seven cases of ovarian metastasis from lung adenocarcinoma from 2013 to 2017 at our institute were investigated. The results were combined with those found in literature review. A total of 16 cases were analyzed in the present study. We examined clinicopathological and immunohistochemical characteristics, further detected ALK rearrangement by FISH (fluorescence in situ hybridization), and assessed EGFR and KRAS mutations using Sanger sequencing or the amplification refractory mutation system (ARMS). RESULTS: The mean age of the patients was 44.6 years (range, 33–56 years). Eleven of sixteen patients developed ovarian tumors within a mean time of 18.5 months (range, 5–48 months) from the initial diagnosis of lung adenocarcinoma; 5 patients had lung tumors and ovarian masses simultaneously. Five tumors (5/16, 31%) occurred in the bilateral ovaries, and the others were unilateral ovarian tumors (11/16, 69%). All seven cases from our institute were positive for TTF-1 and Napsin A but negative for PAX8. In four cases, ALK (D5F3) was diffusely and strongly expressed, with ALK rearrangements (4/7, 57%). Overall, ALK rearrangement was found by FISH or immunohistochemistry in 11/16 (69%) cases. In two cases, EGFR mutations in exons 19 and 21, respectively, were found. One patient did not detected EGFR or ALK mutation in the metastatic tumor, but the primary lung adenocarcinoma did harbor an EGFR mutation. Two cases had no alterations in three genes above. Although the mean survival time of the patients with ALK rearrangement was longer than those without (mean survival time 25 m vs. 20 m), no statistical significance of the difference was found. CONCLUSIONS: As the largest case series of ovarian metastasis from lung adenocarcinoma, our findings indicate that ALK rearrangement is the most common molecular alteration. Although patients with ALK rearrangement appear to have a better prognosis than do those without ALK rearrangement, more cases with longer follow-up and multivariant analysis are needed to clarify this point.
format Online
Article
Text
id pubmed-6712650
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67126502019-08-29 ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma Bi, Rui Bai, Qianming Zhu, Xiaoli Tu, Xiaoyu Cai, Xu Jiang, Wenhua Xu, Xiaoli Tang, Shaoxian Ge, Huijuan Chang, Bin Cheng, Yufan Gan, Hualei Zhou, Xiaoyan Yang, Wentao Diagn Pathol Research BACKGROUND: Ovarian metastatic tumors from lung adenocarcinoma are rare, and a serial study of these tumors is lacking to date. Additionally, a better understanding of the clinicopathological and molecular characteristics of metastatic tumors is needed. METHODS: Seven cases of ovarian metastasis from lung adenocarcinoma from 2013 to 2017 at our institute were investigated. The results were combined with those found in literature review. A total of 16 cases were analyzed in the present study. We examined clinicopathological and immunohistochemical characteristics, further detected ALK rearrangement by FISH (fluorescence in situ hybridization), and assessed EGFR and KRAS mutations using Sanger sequencing or the amplification refractory mutation system (ARMS). RESULTS: The mean age of the patients was 44.6 years (range, 33–56 years). Eleven of sixteen patients developed ovarian tumors within a mean time of 18.5 months (range, 5–48 months) from the initial diagnosis of lung adenocarcinoma; 5 patients had lung tumors and ovarian masses simultaneously. Five tumors (5/16, 31%) occurred in the bilateral ovaries, and the others were unilateral ovarian tumors (11/16, 69%). All seven cases from our institute were positive for TTF-1 and Napsin A but negative for PAX8. In four cases, ALK (D5F3) was diffusely and strongly expressed, with ALK rearrangements (4/7, 57%). Overall, ALK rearrangement was found by FISH or immunohistochemistry in 11/16 (69%) cases. In two cases, EGFR mutations in exons 19 and 21, respectively, were found. One patient did not detected EGFR or ALK mutation in the metastatic tumor, but the primary lung adenocarcinoma did harbor an EGFR mutation. Two cases had no alterations in three genes above. Although the mean survival time of the patients with ALK rearrangement was longer than those without (mean survival time 25 m vs. 20 m), no statistical significance of the difference was found. CONCLUSIONS: As the largest case series of ovarian metastasis from lung adenocarcinoma, our findings indicate that ALK rearrangement is the most common molecular alteration. Although patients with ALK rearrangement appear to have a better prognosis than do those without ALK rearrangement, more cases with longer follow-up and multivariant analysis are needed to clarify this point. BioMed Central 2019-08-28 /pmc/articles/PMC6712650/ /pubmed/31455365 http://dx.doi.org/10.1186/s13000-019-0864-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Bi, Rui
Bai, Qianming
Zhu, Xiaoli
Tu, Xiaoyu
Cai, Xu
Jiang, Wenhua
Xu, Xiaoli
Tang, Shaoxian
Ge, Huijuan
Chang, Bin
Cheng, Yufan
Gan, Hualei
Zhou, Xiaoyan
Yang, Wentao
ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma
title ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma
title_full ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma
title_fullStr ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma
title_full_unstemmed ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma
title_short ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma
title_sort alk rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712650/
https://www.ncbi.nlm.nih.gov/pubmed/31455365
http://dx.doi.org/10.1186/s13000-019-0864-7
work_keys_str_mv AT birui alkrearrangementahighfrequencyalterationinovarianmetastasisfromlungadenocarcinoma
AT baiqianming alkrearrangementahighfrequencyalterationinovarianmetastasisfromlungadenocarcinoma
AT zhuxiaoli alkrearrangementahighfrequencyalterationinovarianmetastasisfromlungadenocarcinoma
AT tuxiaoyu alkrearrangementahighfrequencyalterationinovarianmetastasisfromlungadenocarcinoma
AT caixu alkrearrangementahighfrequencyalterationinovarianmetastasisfromlungadenocarcinoma
AT jiangwenhua alkrearrangementahighfrequencyalterationinovarianmetastasisfromlungadenocarcinoma
AT xuxiaoli alkrearrangementahighfrequencyalterationinovarianmetastasisfromlungadenocarcinoma
AT tangshaoxian alkrearrangementahighfrequencyalterationinovarianmetastasisfromlungadenocarcinoma
AT gehuijuan alkrearrangementahighfrequencyalterationinovarianmetastasisfromlungadenocarcinoma
AT changbin alkrearrangementahighfrequencyalterationinovarianmetastasisfromlungadenocarcinoma
AT chengyufan alkrearrangementahighfrequencyalterationinovarianmetastasisfromlungadenocarcinoma
AT ganhualei alkrearrangementahighfrequencyalterationinovarianmetastasisfromlungadenocarcinoma
AT zhouxiaoyan alkrearrangementahighfrequencyalterationinovarianmetastasisfromlungadenocarcinoma
AT yangwentao alkrearrangementahighfrequencyalterationinovarianmetastasisfromlungadenocarcinoma